Search results
Results From The WOW.Com Content Network
In null-hypothesis significance testing, the p-value [note 1] is the probability of obtaining test results at least as extreme as the result actually observed, under the assumption that the null hypothesis is correct. [2] [3] A very small p-value means that such an extreme observed outcome would be very unlikely under the null hypothesis.
This means that the p-value is a statement about the relation of the data to that hypothesis. [2] The 0.05 significance level is merely a convention. [3] [5] The 0.05 significance level (alpha level) is often used as the boundary between a statistically significant and a statistically non-significant p-value. However, this does not imply that ...
For the null hypothesis to be rejected, an observed result has to be statistically significant, i.e. the observed p-value is less than the pre-specified significance level . To determine whether a result is statistically significant, a researcher calculates a p -value, which is the probability of observing an effect of the same magnitude or ...
The red dashed line indicates the commonly used significance level of 0.05. If the data collection or analysis were to stop at a point where the p-value happened to fall below the significance level, a spurious statistically significant difference could be reported.
Suppose that we take a sample of size n from each of k populations with the same normal distribution N(μ, σ 2) and suppose that ¯ is the smallest of these sample means and ¯ is the largest of these sample means, and suppose S 2 is the pooled sample variance from these samples. Then the following random variable has a Studentized range ...
If the resulting p-value of Levene's test is less than some significance level (typically 0.05), the obtained differences in sample variances are unlikely to have occurred based on random sampling from a population with equal variances. Thus, the null hypothesis of equal variances is rejected and it is concluded that there is a difference ...
On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation. The ...
Although this p-value objectified research outcome, using it as a rigid cut off point can have potentially serious consequences: (i) clinically important differences observed in studies might be statistically non-significant (a type II error, or false negative result) and therefore be unfairly ignored; this often is a result of having a small ...